RxDoctor Payments Data

Hilary Butella

Behavioral Neurology & Neuropsychiatry · The Woodlands, TXNPI 1295221810

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (54.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 51.4% of the total. 2025 is the largest year on record at $25,448, more than ten times the $35 reported in 2020.

$33,630in general payments, 2019–2025

Across 704 payments — averaging $47.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$17K
  • AbbVie$10K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Lundbeck LLC$851
  • Alkermes, Inc.$717
  • Teva Pharmaceuticals USA, Inc.$592
  • plus $3K from 19 others

What the payments were for

  • Consulting fees$3,1889%
  • Speaking & faculty fees$18,21054%
  • Travel & lodging$8863%
  • Food & beverage$11,29334%
  • Education$530%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few behavioral neurology & neuropsychiatry providers in Texasto place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole21$30,544
VraylarCariprazine Hcl14$19,018
TrintellixVortioxetine Hydrobromide12$5,647
Desvenlafaxine Succinate ErDesvenlafaxine Succinate51$2,321
Quetiapine Fumarate52$937
Pregabalin22$510
Bupropion XlBupropion Hcl31$464
Olanzapine16$430
Divalproex Sodium ErDivalproex Sodium13$409
Lamotrigine38$399
Duloxetine Hcl17$333
Ondansetron OdtOndansetron11$298
Trazodone Hcl23$238
Gabapentin21$190
Doxepin Hcl14$180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$1,274$30,54421 claims
AbbVieVraylar$9,517$19,01814 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$452$5,64712 claims
Almatica Pharma LLCSertraline Hcl$148$15322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few behavioral neurology & neuropsychiatry providers in Texason file to place this against a meaningful peer group, so we don't.

Other behavioral neurology & neuropsychiatry in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →